Cyprotex PLC has expanded its toxicology capabilities to include high content 3D tissue analysis and advanced mitochondrial toxicity analysis. These capabilities follow the purchase of new instruments including a Thermo Scientific ArrayScan XTI high content screening (HCS) platform and a Seahorse XF^e extracellular flux analyzer. The new technologies add greater specialization in toxicology and expanded pharmacological efficacy research capabilities.  
 
Regulatory authorities have approved 3D skin models as in vitro alternatives to animal testing. The characteristics of 3D tissue models are more relevant to the in vivo situation than 2D models, and as their complexity evolves (e.g., using stem cells and/or co-culture models) these models will become more predictive, serving as a critical tool in toxicological research, according to the company. 
 
Dr. Anthony Baxter, Cyprotex’s chief executive officer, said,  “Understanding the mechanisms of toxicology of new therapeutics remains a challenging area. Cyprotex is committed to research in this field to help our clients bring safer drugs to the market. By investing in the ArrayScan^TM XTI and the Seahorse XF^e we are equipped with some of the latest cutting-edge technologies, allowing us to expand our current offerings into key specialist areas.”